Wanzenried, Adrian http://orcid.org/0000-0002-3962-8124
Garaiman, Alexandru
Jordan, Suzana
Distler, Oliver
Maurer, Britta
Funding for this research was provided by:
University of Bern
Article History
Received: 19 May 2022
Revised: 5 July 2022
Accepted: 6 July 2022
First Online: 29 July 2022
Declarations
:
: Ethics approval was obtained from the Zurich Ethics Committee (BASEC-Nr. 2020–00387).
: Informed consent was obtained from all participants.
: AW, IG and SJ have no competing interests to declare. OD had consultancy relationship and/or has received research funding from Abbvie, Actelion, Acceleron Pharma, Amgen, AnaMar, Baecon Discovery, Blade Therapeutics, Bayer, Boehringer Ingelheim, Catenion, Competitive Drug Development International Ltd., CSL Behring, ChemomAb, Curzion Pharmaceuticals, Ergonex, Galapagos NV, Glenmark Pharmaceuticals, GSK, Inventiva, Italfarmaco, iQone, iQvia, Lilly, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Roche, Sanofi, Target Bio Science and UCB in the area of potential treatments of scleroderma and its complications. In addition, OD has a patent mir-29 for the treatment of systemic sclerosis issued (US8247389, EP2331143). BM had grant/research support from AbbVie, Protagen and Novartis Biomedical Research and a consultancy relationship with Boehringer-Ingelheim as well as congress support from Pfizer, Roche, Actelion, mepha and MSD. In addition, BM has a patent mir-29 for the treatment of systemic sclerosis issued (US8247389, EP2331143).